82TiP A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies

Saved in:
Bibliographic Details
Published inJournal of thoracic oncology Vol. 18; no. 4; pp. S87 - S88
Main Authors Gianoukakis, A.G., Arnold, S.M., Kahn, S.A., Taylor, M., Garralda, E., Krebs, M.G., Arkenau, H-T., Clark, L., Fisher, G., Subbiah, V.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.04.2023
Online AccessGet full text

Cover

More Information
ISSN:1556-0864
1556-1380
DOI:10.1016/S1556-0864(23)00336-2